Benlysta mg solution for injection in pre-filled syringe. 2. available information, dose adjustment is not required in patients with mild, moderate or severe. Learn about BENLYSTA (belimumab), an FDA-approved prescription infusion or self-injectable lupus medication to help treat your Request your FREE Info Kit. Belimumab (Benlysta) is a biologic reference with prescribing information, dosage, medication administration, and possible side effects.

Author: Moogukasa Tygora
Country: Liberia
Language: English (Spanish)
Genre: Art
Published (Last): 14 July 2008
Pages: 103
PDF File Size: 4.69 Mb
ePub File Size: 17.53 Mb
ISBN: 997-6-64385-448-3
Downloads: 6090
Price: Free* [*Free Regsitration Required]
Uploader: Vushakar

Treatment was immediately initiated with glucocorticosteroids GCSmycophenolate mofetil MMF and hydroxychloroquine sulphate Plaquenil. Dobrowolski C, Erkan Ingormation. While therapeutic advances in immunosuppressive drugs e. Results of a randomized, double-blind, placebo-controlled, pilot trial. In a phase-II, multi-center, placebo-controlled, double-blind study, Hewett and colleagues examined the safety and efficacy of belimumab in patients with generalized MG who remained symptomatic despite standard of care SoC therapy.

Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity. Abstracts of international conferences up to October were also included. Benkysta recent discoveries may enable a paradigm shift in the treatment of this complex disease, allowing the tailoring of treatment to target specific pathogenic mediators at specific points in time in the progression of disease.

In a phase II clinical trial, De Vita and colleagues examined the safety and effectiveness of long-term treatment of SS with belimumab. GSK; July 21, Tacrolimus was associated but no effect was observed with the proteinuria remaining in the nephrotic range and secondary effects of the glucocorticoids becoming a real concern.

Belimumab (Benlysta) – Medical Clinical Policy Bulletins | Aetna

The authors concluded that the primary end-point was not met for belimumab in participants with generalized MG receiving Benlysha. The authors concluded that these results suggested that the clinical effectiveness of belimumab for RA needs to be further investigated in future clinical trials. Rituximab has proven efficacy in remission induction therapy for AAV, and 2 trials with rituximab as remission maintenance therapy are ongoing.


These researchers reviewed the literature on B cell-directed therapies in human and experimental APS.

Extension of a phase II, double-blind, placebo-controlled, dose-ranging study. The authors concluded that belimumab has the potential to be the first targeted biological treatment that is approved specifically for SLE, providing a new option for the management of this important prototypic autoimmune disease.

Links to various non-Aetna sites are provided for your convenience only. Belimumab has not been evaluated and is not recommended in patients with severe active lupus nephritis or severe active central nervous system lupus or in combination with other biologic products or cyclophosphamide. Clinical Policy Bulletin Notes. Autologous stem cell transplantation showed the best therapeutic efficacy on skin and internal organs, and looks very promising, as modification of transplantation immunosuppression is decreasing the early high mortality.

Additionally, these criteria are often used in clinical practice as a guide to help facilitate the diagnosis of SLE. A total of 18 articles 13 of rituximab, 3 of belimumab, 1 of epratuzumab and 1 of baminercept were identified for detailed evaluation; 4 randomized controlled trials RCTs of rituximab treatment versus placebo involving presdribing were included for quantitative analysis.

In both human and murine studies, B cell-directed therapies appeared to have clinical and serologic beneficial effects including a decrease in the anti-phospholipid antibody titers after treatment. Jin and Ding summarized up-to-date pharmacological and clinical data of belimumab in the treatment of rheumatoid arthritis RA. The median time to first SLE flare was 67 days in the combined belimumab group versus 83 days in the placebo group.

Belimumab (Benlysta)

Systemic lupus erythematosus SLE. When SLE flares, it can present as chest pain, fatigue, fever, hair loss, rash, light sensitivity, as well as swelling in the joints and joint pain Finnish Medical Society, Monoclonal antibodies directed against different components of the immune system have appeared, along with new drugs from the hematology field.


Dexamethasone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram. Immunotherapy informayion systemic sclerosis. Preclinical and clinical studies suggest that belimumab can reduce autoantibody informahion in SLE. Aran AA, Putterman C. Significant differences between the treatment and placebo groups were not attained for either primary end point, and no dose response was observed. In the subgroup Research progress on B cell surface molecules targeted therapy in rheumatoid arthritis.

Oral or nasopharyngeal ulceration, usually painless, observed by a physician. Finally, biologic therapies are effective also in gout, mainly targeting IL-1 to block the inflammasome.

There was only a modest decrease in the frequency of total IgM-producing, but not IgG-producing, cells on days andconsistent with the phenotypic and serologic data. Arthritis Care Res Hoboken ;64 6: A literature search was performed on PubMed using keywords, including belimumab, LymphoStat-B, benlysta, BLyS inhibitor, rheumatoid arthritis and autoimmune disease.

In addition, the roles of aberrant expression of microRNAs and pro-inflammatory cytokines have been explored. Among the 30 patients recruited, 28 were evaluated benlyta week 28 as already reported; 19 terminated the week study, 15 of them informationn responders and 4 non-responders at week 28; 13 of the 15 responders at week 28 also responded at week 52